Cyclacel
Cell cycle pioneers improving patients' healthcare with orally available innovative medicines

Cell cycle pioneers improving patients' healthcare
with orally available innovative medicines

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases.

Our Pipeline

Applying its core strength in cell cycle biology, Cyclacel is advancing a pipeline of orally available, small molecule, investigational drugs designed to stop uncontrolled cell division. Sapacitabine, our lead drug candidate, is being evaluated in the SEAMLESS pivotal Phase 3 trial in elderly patients with acute myeloid leukemia under a Special Protocol Assessment agreement with the US Food and Drug Administration. For more information on our investigational drug programs and clinical trials, please go to the Research & Development tab above.

Learn more about our clinical trials:

Sapacitabine (CYC682)

An oral nucleoside analogue prodrug that acts through a novel mechanism.

Seliciclib (CYC202)

A novel, first-in-class, orally available, cyclin dependent kinase (CDK) inhibitor.

CYC116

An orally-active inhibitor of Aurora kinases A & B and VEGFR2.

Common Stock Info

NASDAQGM: CYCC US$

Delayed at least 20 minutes.
Provided by eSignal.

Recent News

The SEAMLESS Study